News
-
-
COMMUNIQUÉ DE PRESSE
Medicus Pharma Ltd. Receives Full United Kingdom Regulatory and Ethical Approvals To Expand Phase 2 Clinical Study (SKNJCT-003) To Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin
Medicus Pharma Ltd. expands SKNJCT-003 clinical study to the United Kingdom for global patient recruitment. Approvals received from U.K. regulatory bodies enabling pivotal study -
-
-
COMMUNIQUÉ DE PRESSE
Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for Skinject(TM) in Patients with Gorlin Syndrome
Medicus Pharma collaborates with the Gorlin Syndrome Alliance to provide compassionate access to SKINJECT™, a novel therapy for Gorlin Syndrome patients. The initiative aims to collect real-world data and integrate patient insights for future development -
-
-
COMMUNIQUÉ DE PRESSE
Medicus Pharma Ltd. Announces First Patient Treated in United Arab Emirates (UAE) Sknjct-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin
Medicus Pharma enrolls first patient in SKNJCT-004 phase 2 clinical study for non-invasive BCC treatment in UAE with Cleveland Clinic Abu Dhabi as lead investigator -
-
